Champions Oncology Inc (CSBR)
4.53
+0.03
(+0.67%)
USD |
NASDAQ |
May 31, 16:00
Champions Oncology Enterprise Value: 57.11M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 57.11M |
| May 30, 2024 | 56.70M |
| May 29, 2024 | 58.20M |
| May 28, 2024 | 57.66M |
| May 24, 2024 | 56.98M |
| May 23, 2024 | 58.47M |
| May 22, 2024 | 59.15M |
| May 21, 2024 | 59.63M |
| May 20, 2024 | 60.24M |
| May 17, 2024 | 59.42M |
| May 16, 2024 | 59.83M |
| May 15, 2024 | 60.96M |
| May 14, 2024 | 58.61M |
| May 13, 2024 | 59.83M |
| May 10, 2024 | 61.19M |
| May 09, 2024 | 62.96M |
| May 08, 2024 | 61.60M |
| May 07, 2024 | 59.97M |
| May 06, 2024 | 62.14M |
| May 03, 2024 | 65.27M |
| May 02, 2024 | 61.72M |
| May 01, 2024 | 61.60M |
| April 30, 2024 | 61.46M |
| April 29, 2024 | 62.41M |
| April 26, 2024 | 63.77M |
| Date | Value |
|---|---|
| April 25, 2024 | 64.32M |
| April 24, 2024 | 63.91M |
| April 23, 2024 | 64.45M |
| April 22, 2024 | 64.32M |
| April 19, 2024 | 64.32M |
| April 18, 2024 | 64.38M |
| April 17, 2024 | 63.91M |
| April 16, 2024 | 66.56M |
| April 15, 2024 | 63.50M |
| April 12, 2024 | 63.50M |
| April 11, 2024 | 62.46M |
| April 10, 2024 | 62.69M |
| April 09, 2024 | 63.23M |
| April 08, 2024 | 63.23M |
| April 05, 2024 | 61.60M |
| April 04, 2024 | 63.09M |
| April 03, 2024 | 63.68M |
| April 02, 2024 | 64.45M |
| April 01, 2024 | 62.28M |
| March 28, 2024 | 62.14M |
| March 27, 2024 | 62.69M |
| March 26, 2024 | 63.77M |
| March 25, 2024 | 66.22M |
| March 22, 2024 | 68.94M |
| March 21, 2024 | 67.85M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
40.02M
Minimum
Dec 20 2022
176.69M
Maximum
Mar 16 2021
93.47M
Average
91.12M
Median
Enterprise Value Benchmarks
| AIM ImmunoTech Inc | 10.88M |
| Perspective Therapeutics Inc | 680.29M |
| Protalix BioTherapeutics Inc | 54.78M |
| Electromed Inc | 114.83M |
| Armata Pharmaceuticals Inc | 192.52M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.53M |
| Revenue (Quarterly) | 12.02M |
| Total Expenses (Quarterly) | 14.60M |
| EPS Diluted (Quarterly) | -0.19 |
| Gross Profit Margin (Quarterly) | 34.70% |
| Profit Margin (Quarterly) | -21.05% |
| Earnings Yield | -15.89% |
| Normalized Earnings Yield | -15.89 |